AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie lupron (leuprolide) [legacy through FY21] — International net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2021
179
Period ended Dec 31, 2021
Change on a year earlier
+17.8%
152 in FY2020
History
6 years
Since FY2016
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lupron (leuprolide) [legacy through FY21] — International net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 179 | +17.8% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 152 | -9.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 167 | +0.6% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 166 | +3.8% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 160 | +1.3% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 158 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up lupron (leuprolide) [legacy through fy21] — international net revenues ($m)
Cite this data
StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] — International net revenues ($M) ($M), annual FY2016–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron_intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.